OBJECTIVES: We report cardiac function of @entity1 treated for @entity3052 with chemotherapy only according to three consecutive Nordic protocols. METHODS: Ninety-eight of 138 eligible @entity1 accepted examination with standardized echocardiography. Results were compared with age- and sex-matched controls. RESULTS: The median age was 3 yr at diagnosis (range 0-15), and the median time from diagnosis to study was 11 yr (4-25). All but one @entity1 had received @entity632 and 90% had received @entity2664 . The median cumulative dose of @entity5699 equivalents was 300 mg/m(2) (210-525). @entity1002 ( @entity1002 ) and ejection fraction (LVEF) were lower in @entity1 than in controls (32.6% (SD 4.0) vs. 35.2% (SD 3.4), P = 0.002 and 59.9% (SD 5.5) vs. 64.2% (SD 4.4), P = 0.001). The myocardial performance index (MPI) was higher in @entity1 than in controls (0.32 (SD 0.081) vs. 0.26 (SD 0.074), P < 0.0001). Cumulative dose of @entity632 but not @entity2664 was related to lower @entity1002 (P = 0.037) and LVEF (P = 0.016). Longer follow-up was associated with lower @entity1002 (P = 0.034). Higher MPI was associated with young age at diagnosis (P = 0.04) and longer follow-up (P = 0.031). CONCLUSIONS: In this study, most @entity1 had cardiac function within normal limits and reported very few cardiac symptoms. However, compared with healthy controls, they had significantly reduced left ventricular function.

Cardiac function in survivors of childhood XXXX treated with chemotherapy only: a NOPHO-AML study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity5699 :: ('MESH:D003630', 'Chemical') :: ['daunorubicin'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['Childhood acute myeloid leukemia'] @entity1002 :: ('MESH:D018487', 'Disease') :: ['LVFS', 'Left ventricular fractional shortening']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']
